instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Treatment failure'. | Disseminated Lomentospora prolificans infection presenting with arterial exsanguination.
Lomentospora prolificans is an opportunistic fungal pathogen found especially in Australia, Spain, Portugal, California, and the southern United States. Although it causes a wide spectrum of infections, disseminated L. prolificans ... | AMPHOTERICIN B, POSACONAZOLE, PREDNISONE, TACROLIMUS, TERBINAFINE, VORICONAZOLE | DrugsGivenReaction | CC BY-NC-ND | 34849438 | 20,791,878 | 2021-12 |
What was the administration route of drug 'POSACONAZOLE'? | Disseminated Lomentospora prolificans infection presenting with arterial exsanguination.
Lomentospora prolificans is an opportunistic fungal pathogen found especially in Australia, Spain, Portugal, California, and the southern United States. Although it causes a wide spectrum of infections, disseminated L. prolificans ... | Oral | DrugAdministrationRoute | CC BY-NC-ND | 34849438 | 20,298,646 | 2021-12 |
What was the outcome of reaction 'Drug ineffective for unapproved indication'? | Disseminated Lomentospora prolificans infection presenting with arterial exsanguination.
Lomentospora prolificans is an opportunistic fungal pathogen found especially in Australia, Spain, Portugal, California, and the southern United States. Although it causes a wide spectrum of infections, disseminated L. prolificans ... | Fatal | ReactionOutcome | CC BY-NC-ND | 34849438 | 20,212,707 | 2021-12 |
What was the outcome of reaction 'Exsanguination'? | Disseminated Lomentospora prolificans infection presenting with arterial exsanguination.
Lomentospora prolificans is an opportunistic fungal pathogen found especially in Australia, Spain, Portugal, California, and the southern United States. Although it causes a wide spectrum of infections, disseminated L. prolificans ... | Fatal | ReactionOutcome | CC BY-NC-ND | 34849438 | 20,750,089 | 2021-12 |
What was the outcome of reaction 'Fungal infection'? | Disseminated Lomentospora prolificans infection presenting with arterial exsanguination.
Lomentospora prolificans is an opportunistic fungal pathogen found especially in Australia, Spain, Portugal, California, and the southern United States. Although it causes a wide spectrum of infections, disseminated L. prolificans ... | Fatal | ReactionOutcome | CC BY-NC-ND | 34849438 | 20,791,878 | 2021-12 |
What was the outcome of reaction 'Off label use'? | Disseminated Lomentospora prolificans infection presenting with arterial exsanguination.
Lomentospora prolificans is an opportunistic fungal pathogen found especially in Australia, Spain, Portugal, California, and the southern United States. Although it causes a wide spectrum of infections, disseminated L. prolificans ... | Fatal | ReactionOutcome | CC BY-NC-ND | 34849438 | 20,212,707 | 2021-12 |
What was the outcome of reaction 'Scedosporium infection'? | Disseminated Lomentospora prolificans infection presenting with arterial exsanguination.
Lomentospora prolificans is an opportunistic fungal pathogen found especially in Australia, Spain, Portugal, California, and the southern United States. Although it causes a wide spectrum of infections, disseminated L. prolificans ... | Fatal | ReactionOutcome | CC BY-NC-ND | 34849438 | 20,807,084 | 2021-12 |
What was the outcome of reaction 'Treatment failure'? | Disseminated Lomentospora prolificans infection presenting with arterial exsanguination.
Lomentospora prolificans is an opportunistic fungal pathogen found especially in Australia, Spain, Portugal, California, and the southern United States. Although it causes a wide spectrum of infections, disseminated L. prolificans ... | Fatal | ReactionOutcome | CC BY-NC-ND | 34849438 | 20,791,878 | 2021-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cholestasis'. | Management of pregnancy with diffuse cutaneous systemic sclerosis: a case report and literature review.
Diffuse cutaneous systemic sclerosis may occur in women of childbearing age. Pregnancies in this population are associated with a markedly increased risk of adverse obstetric and maternal outcomes even before the ons... | ASPIRIN, METHYLPREDNISOLONE, URSODIOL | DrugsGivenReaction | CC BY-NC | 34851779 | 20,472,200 | 2021-11 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Exposure during pregnancy'. | Management of pregnancy with diffuse cutaneous systemic sclerosis: a case report and literature review.
Diffuse cutaneous systemic sclerosis may occur in women of childbearing age. Pregnancies in this population are associated with a markedly increased risk of adverse obstetric and maternal outcomes even before the ons... | ASPIRIN, METHYLPREDNISOLONE, URSODIOL | DrugsGivenReaction | CC BY-NC | 34851779 | 20,472,200 | 2021-11 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Live birth'. | Management of pregnancy with diffuse cutaneous systemic sclerosis: a case report and literature review.
Diffuse cutaneous systemic sclerosis may occur in women of childbearing age. Pregnancies in this population are associated with a markedly increased risk of adverse obstetric and maternal outcomes even before the ons... | ASPIRIN, METHYLPREDNISOLONE, URSODIOL | DrugsGivenReaction | CC BY-NC | 34851779 | 20,472,200 | 2021-11 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Maternal exposure during delivery'. | Management of pregnancy with diffuse cutaneous systemic sclerosis: a case report and literature review.
Diffuse cutaneous systemic sclerosis may occur in women of childbearing age. Pregnancies in this population are associated with a markedly increased risk of adverse obstetric and maternal outcomes even before the ons... | ASPIRIN, BUPIVACAINE, FENTANYL, METHYLPREDNISOLONE, OXYTOCIN, URSODIOL | DrugsGivenReaction | CC BY-NC | 34851779 | 20,444,568 | 2021-11 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Maternal exposure during pregnancy'. | Management of pregnancy with diffuse cutaneous systemic sclerosis: a case report and literature review.
Diffuse cutaneous systemic sclerosis may occur in women of childbearing age. Pregnancies in this population are associated with a markedly increased risk of adverse obstetric and maternal outcomes even before the ons... | ASPIRIN, BUPIVACAINE, FENTANYL, METHYLPREDNISOLONE, OXYTOCIN, URSODIOL | DrugsGivenReaction | CC BY-NC | 34851779 | 20,444,568 | 2021-11 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Normal newborn'. | Management of pregnancy with diffuse cutaneous systemic sclerosis: a case report and literature review.
Diffuse cutaneous systemic sclerosis may occur in women of childbearing age. Pregnancies in this population are associated with a markedly increased risk of adverse obstetric and maternal outcomes even before the ons... | ASPIRIN, BUPIVACAINE, FENTANYL, METHYLPREDNISOLONE, OXYTOCIN, URSODIOL | DrugsGivenReaction | CC BY-NC | 34851779 | 20,444,568 | 2021-11 |
What was the administration route of drug 'BUPIVACAINE'? | Management of pregnancy with diffuse cutaneous systemic sclerosis: a case report and literature review.
Diffuse cutaneous systemic sclerosis may occur in women of childbearing age. Pregnancies in this population are associated with a markedly increased risk of adverse obstetric and maternal outcomes even before the ons... | Intrathecal | DrugAdministrationRoute | CC BY-NC | 34851779 | 20,444,568 | 2021-11 |
What was the administration route of drug 'FENTANYL'? | Management of pregnancy with diffuse cutaneous systemic sclerosis: a case report and literature review.
Diffuse cutaneous systemic sclerosis may occur in women of childbearing age. Pregnancies in this population are associated with a markedly increased risk of adverse obstetric and maternal outcomes even before the ons... | Epidural | DrugAdministrationRoute | CC BY-NC | 34851779 | 20,444,568 | 2021-11 |
What was the administration route of drug 'URSODIOL'? | Management of pregnancy with diffuse cutaneous systemic sclerosis: a case report and literature review.
Diffuse cutaneous systemic sclerosis may occur in women of childbearing age. Pregnancies in this population are associated with a markedly increased risk of adverse obstetric and maternal outcomes even before the ons... | Topical | DrugAdministrationRoute | CC BY-NC | 34851779 | 20,444,568 | 2021-11 |
What was the dosage of drug 'BUPIVACAINE'? | Management of pregnancy with diffuse cutaneous systemic sclerosis: a case report and literature review.
Diffuse cutaneous systemic sclerosis may occur in women of childbearing age. Pregnancies in this population are associated with a markedly increased risk of adverse obstetric and maternal outcomes even before the ons... | 2.5 MG | DrugDosageText | CC BY-NC | 34851779 | 20,444,568 | 2021-11 |
What was the dosage of drug 'FENTANYL'? | Management of pregnancy with diffuse cutaneous systemic sclerosis: a case report and literature review.
Diffuse cutaneous systemic sclerosis may occur in women of childbearing age. Pregnancies in this population are associated with a markedly increased risk of adverse obstetric and maternal outcomes even before the ons... | 15 MG | DrugDosageText | CC BY-NC | 34851779 | 20,444,568 | 2021-11 |
What was the dosage of drug 'OXYTOCIN'? | Management of pregnancy with diffuse cutaneous systemic sclerosis: a case report and literature review.
Diffuse cutaneous systemic sclerosis may occur in women of childbearing age. Pregnancies in this population are associated with a markedly increased risk of adverse obstetric and maternal outcomes even before the ons... | OXYTOCIN INFUSION WAS ADMINISTERED THROUGH DOUBLE-BALLOON DEVICE | DrugDosageText | CC BY-NC | 34851779 | 20,444,568 | 2021-11 |
What was the outcome of reaction 'Maternal exposure during delivery'? | Management of pregnancy with diffuse cutaneous systemic sclerosis: a case report and literature review.
Diffuse cutaneous systemic sclerosis may occur in women of childbearing age. Pregnancies in this population are associated with a markedly increased risk of adverse obstetric and maternal outcomes even before the ons... | Recovered | ReactionOutcome | CC BY-NC | 34851779 | 20,444,568 | 2021-11 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Constipation'. | A case of improvement of clozapine-induced low leukocyte counts by adenine, cepharanthin and ninjin-yoei-to in a patient with treatment-resistant schizophrenia.
BACKGROUND
Although clozapine is the optimal drug for patients with treatment-resistant schizophrenia, the drug has harmful adverse effects such as leukopenia.... | ADENINE, BIPERIDEN, CLOZAPINE, ETIZOLAM, FLUNITRAZEPAM, OLANZAPINE, QUETIAPINE | DrugsGivenReaction | CC BY | 34852834 | 20,263,824 | 2021-12-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neutrophil count decreased'. | A case of improvement of clozapine-induced low leukocyte counts by adenine, cepharanthin and ninjin-yoei-to in a patient with treatment-resistant schizophrenia.
BACKGROUND
Although clozapine is the optimal drug for patients with treatment-resistant schizophrenia, the drug has harmful adverse effects such as leukopenia.... | BIPERIDEN, CLOZAPINE, ETIZOLAM, FLUNITRAZEPAM, LITHIUM CARBONATE, OLANZAPINE, QUETIAPINE | DrugsGivenReaction | CC BY | 34852834 | 20,210,292 | 2021-12-02 |
What is the weight of the patient? | A case of improvement of clozapine-induced low leukocyte counts by adenine, cepharanthin and ninjin-yoei-to in a patient with treatment-resistant schizophrenia.
BACKGROUND
Although clozapine is the optimal drug for patients with treatment-resistant schizophrenia, the drug has harmful adverse effects such as leukopenia.... | 66.6 kg. | Weight | CC BY | 34852834 | 20,210,292 | 2021-12-02 |
What was the dosage of drug 'ADENINE'? | A case of improvement of clozapine-induced low leukocyte counts by adenine, cepharanthin and ninjin-yoei-to in a patient with treatment-resistant schizophrenia.
BACKGROUND
Although clozapine is the optimal drug for patients with treatment-resistant schizophrenia, the drug has harmful adverse effects such as leukopenia.... | UNK (20MG, 30MG) | DrugDosageText | CC BY | 34852834 | 20,263,824 | 2021-12-02 |
What was the outcome of reaction 'Constipation'? | A case of improvement of clozapine-induced low leukocyte counts by adenine, cepharanthin and ninjin-yoei-to in a patient with treatment-resistant schizophrenia.
BACKGROUND
Although clozapine is the optimal drug for patients with treatment-resistant schizophrenia, the drug has harmful adverse effects such as leukopenia.... | Recovering | ReactionOutcome | CC BY | 34852834 | 20,263,824 | 2021-12-02 |
What was the outcome of reaction 'Neutrophil count decreased'? | A case of improvement of clozapine-induced low leukocyte counts by adenine, cepharanthin and ninjin-yoei-to in a patient with treatment-resistant schizophrenia.
BACKGROUND
Although clozapine is the optimal drug for patients with treatment-resistant schizophrenia, the drug has harmful adverse effects such as leukopenia.... | Recovering | ReactionOutcome | CC BY | 34852834 | 20,210,292 | 2021-12-02 |
What was the outcome of reaction 'White blood cell count decreased'? | A case of improvement of clozapine-induced low leukocyte counts by adenine, cepharanthin and ninjin-yoei-to in a patient with treatment-resistant schizophrenia.
BACKGROUND
Although clozapine is the optimal drug for patients with treatment-resistant schizophrenia, the drug has harmful adverse effects such as leukopenia.... | Recovering | ReactionOutcome | CC BY | 34852834 | 20,263,824 | 2021-12-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'COVID-19 pneumonia'. | Discrepant Antigen-specific Antibody Responses Causing SARS-CoV-2 Persistence in a Patient Receiving B-cell-targeted Therapy with Rituximab.
A 73-year-old man previously treated with rituximab for his mucosa-associated lymphoid tissue lymphoma suffered a suboptimal humoral immune response against an acquired SARS-CoV-2... | RITUXIMAB | DrugsGivenReaction | CC BY-NC-ND | 34853259 | 20,189,301 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Immune system disorder'. | Discrepant Antigen-specific Antibody Responses Causing SARS-CoV-2 Persistence in a Patient Receiving B-cell-targeted Therapy with Rituximab.
A 73-year-old man previously treated with rituximab for his mucosa-associated lymphoid tissue lymphoma suffered a suboptimal humoral immune response against an acquired SARS-CoV-2... | RITUXIMAB | DrugsGivenReaction | CC BY-NC-ND | 34853259 | 20,189,301 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapeutic product ineffective for unapproved indication'. | Discrepant Antigen-specific Antibody Responses Causing SARS-CoV-2 Persistence in a Patient Receiving B-cell-targeted Therapy with Rituximab.
A 73-year-old man previously treated with rituximab for his mucosa-associated lymphoid tissue lymphoma suffered a suboptimal humoral immune response against an acquired SARS-CoV-2... | CHLOROQUINE, FAVIPIRAVIR, METHYLPREDNISOLONE | DrugsGivenReaction | CC BY-NC-ND | 34853259 | 20,214,288 | 2021 |
What was the dosage of drug 'IVERMECTIN'? | Discrepant Antigen-specific Antibody Responses Causing SARS-CoV-2 Persistence in a Patient Receiving B-cell-targeted Therapy with Rituximab.
A 73-year-old man previously treated with rituximab for his mucosa-associated lymphoid tissue lymphoma suffered a suboptimal humoral immune response against an acquired SARS-CoV-2... | 15 MILLIGRAM | DrugDosageText | CC BY-NC-ND | 34853259 | 20,292,056 | 2021 |
What was the dosage of drug 'RITUXIMAB'? | Discrepant Antigen-specific Antibody Responses Causing SARS-CoV-2 Persistence in a Patient Receiving B-cell-targeted Therapy with Rituximab.
A 73-year-old man previously treated with rituximab for his mucosa-associated lymphoid tissue lymphoma suffered a suboptimal humoral immune response against an acquired SARS-CoV-2... | EIGHT DOSES | DrugDosageText | CC BY-NC-ND | 34853259 | 20,292,056 | 2021 |
What was the outcome of reaction 'COVID-19 pneumonia'? | Discrepant Antigen-specific Antibody Responses Causing SARS-CoV-2 Persistence in a Patient Receiving B-cell-targeted Therapy with Rituximab.
A 73-year-old man previously treated with rituximab for his mucosa-associated lymphoid tissue lymphoma suffered a suboptimal humoral immune response against an acquired SARS-CoV-2... | Fatal | ReactionOutcome | CC BY-NC-ND | 34853259 | 20,189,301 | 2021 |
What was the outcome of reaction 'Off label use'? | Discrepant Antigen-specific Antibody Responses Causing SARS-CoV-2 Persistence in a Patient Receiving B-cell-targeted Therapy with Rituximab.
A 73-year-old man previously treated with rituximab for his mucosa-associated lymphoid tissue lymphoma suffered a suboptimal humoral immune response against an acquired SARS-CoV-2... | Fatal | ReactionOutcome | CC BY-NC-ND | 34853259 | 20,214,288 | 2021 |
What was the outcome of reaction 'Therapeutic product ineffective for unapproved indication'? | Discrepant Antigen-specific Antibody Responses Causing SARS-CoV-2 Persistence in a Patient Receiving B-cell-targeted Therapy with Rituximab.
A 73-year-old man previously treated with rituximab for his mucosa-associated lymphoid tissue lymphoma suffered a suboptimal humoral immune response against an acquired SARS-CoV-2... | Fatal | ReactionOutcome | CC BY-NC-ND | 34853259 | 20,214,288 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disease progression'. | Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition.
Acquired resistance to molecular targeted therapy is a significant challenge of the precision medicine era. The ability to understand these mechanisms of resistance may improve patient selec... | CISPLATIN, GEMCITABINE | DrugsGivenReaction | CC BY | 34853384 | 20,734,273 | 2021-12-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition.
Acquired resistance to molecular targeted therapy is a significant challenge of the precision medicine era. The ability to understand these mechanisms of resistance may improve patient selec... | CISPLATIN, GEMCITABINE | DrugsGivenReaction | CC BY | 34853384 | 20,704,501 | 2021-12-01 |
What was the outcome of reaction 'Disease progression'? | Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition.
Acquired resistance to molecular targeted therapy is a significant challenge of the precision medicine era. The ability to understand these mechanisms of resistance may improve patient selec... | Recovering | ReactionOutcome | CC BY | 34853384 | 20,734,273 | 2021-12-01 |
What was the administration route of drug 'ACYCLOVIR'? | COVID-19-associated encephalitis or Creutzfeldt-Jakob disease: a case report.
Background: Accurate diagnosis and management of patients with rapidly progressive dementia may be challenging during the COVID-19 pandemic, which has negatively influenced the diagnostic performances, medical resource allocation and routine ... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34854312 | 20,878,207 | 2021-12-02 |
What was the administration route of drug 'METHYLPREDNISOLONE ACETATE'? | COVID-19-associated encephalitis or Creutzfeldt-Jakob disease: a case report.
Background: Accurate diagnosis and management of patients with rapidly progressive dementia may be challenging during the COVID-19 pandemic, which has negatively influenced the diagnostic performances, medical resource allocation and routine ... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34854312 | 20,878,207 | 2021-12-02 |
What was the outcome of reaction 'Drug ineffective'? | COVID-19-associated encephalitis or Creutzfeldt-Jakob disease: a case report.
Background: Accurate diagnosis and management of patients with rapidly progressive dementia may be challenging during the COVID-19 pandemic, which has negatively influenced the diagnostic performances, medical resource allocation and routine ... | Fatal | ReactionOutcome | CC BY | 34854312 | 20,878,207 | 2021-12-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug reaction with eosinophilia and systemic symptoms'. | Sulfasalazine-induced drug rash with eosinophilia and systemic symptoms syndrome in a seronegative spondyloarthritis patient: A Case report.
The objectives were to evaluate drug rash with eosinophilia and systemic symptoms syndrome due to sulfasalazine and to carry out the pharmacoeconomic assessment associated with th... | METHOTREXATE, SULFASALAZINE | DrugsGivenReaction | CC BY-NC-SA | 34854409 | 20,563,224 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pneumonitis'. | Sulfasalazine-induced drug rash with eosinophilia and systemic symptoms syndrome in a seronegative spondyloarthritis patient: A Case report.
The objectives were to evaluate drug rash with eosinophilia and systemic symptoms syndrome due to sulfasalazine and to carry out the pharmacoeconomic assessment associated with th... | METHOTREXATE, SULFASALAZINE | DrugsGivenReaction | CC BY-NC-SA | 34854409 | 20,563,224 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Immune reconstitution inflammatory syndrome'. | Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy.
Atezolizumab successfully reinvigorated JC virus immunity in a patient in Belgium with progressive multifocal leukoencephalopathy, as demonstrated by clinical, virologic, and radiologic response to treatment. However, the treatment also resulted in ... | ATEZOLIZUMAB, CHLORAMBUCIL, OBINUTUZUMAB | DrugsGivenReaction | CC BY | 34856110 | 20,688,904 | 2021-12-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Immune system disorder'. | Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy.
Atezolizumab successfully reinvigorated JC virus immunity in a patient in Belgium with progressive multifocal leukoencephalopathy, as demonstrated by clinical, virologic, and radiologic response to treatment. However, the treatment also resulted in ... | ATEZOLIZUMAB, CHLORAMBUCIL, OBINUTUZUMAB | DrugsGivenReaction | CC BY | 34856110 | 20,688,904 | 2021-12-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Progressive multifocal leukoencephalopathy'. | Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy.
Atezolizumab successfully reinvigorated JC virus immunity in a patient in Belgium with progressive multifocal leukoencephalopathy, as demonstrated by clinical, virologic, and radiologic response to treatment. However, the treatment also resulted in ... | ATEZOLIZUMAB, CHLORAMBUCIL, OBINUTUZUMAB | DrugsGivenReaction | CC BY | 34856110 | 20,688,904 | 2021-12-02 |
What was the administration route of drug 'OBINUTUZUMAB'? | Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy.
Atezolizumab successfully reinvigorated JC virus immunity in a patient in Belgium with progressive multifocal leukoencephalopathy, as demonstrated by clinical, virologic, and radiologic response to treatment. However, the treatment also resulted in ... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34856110 | 20,688,904 | 2021-12-02 |
What was the outcome of reaction 'Immune reconstitution inflammatory syndrome'? | Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy.
Atezolizumab successfully reinvigorated JC virus immunity in a patient in Belgium with progressive multifocal leukoencephalopathy, as demonstrated by clinical, virologic, and radiologic response to treatment. However, the treatment also resulted in ... | Recovering | ReactionOutcome | CC BY | 34856110 | 20,688,904 | 2021-12-02 |
What was the outcome of reaction 'Immune system disorder'? | Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy.
Atezolizumab successfully reinvigorated JC virus immunity in a patient in Belgium with progressive multifocal leukoencephalopathy, as demonstrated by clinical, virologic, and radiologic response to treatment. However, the treatment also resulted in ... | Recovering | ReactionOutcome | CC BY | 34856110 | 20,688,904 | 2021-12-02 |
What was the outcome of reaction 'Progressive multifocal leukoencephalopathy'? | Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy.
Atezolizumab successfully reinvigorated JC virus immunity in a patient in Belgium with progressive multifocal leukoencephalopathy, as demonstrated by clinical, virologic, and radiologic response to treatment. However, the treatment also resulted in ... | Fatal | ReactionOutcome | CC BY | 34856110 | 20,688,904 | 2021-12-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Managing solar retinopathy with suprachoroidal triamcinolone acetonide injection in a young girl: a case report.
BACKGROUND
Solar retinopathy is a disease that causes photochemical toxicity in the retinal fovea tissues, leading to an acute decrease of vision.
METHODS
This case report is an interventional case of an a... | TRIAMCINOLONE ACETONIDE | DrugsGivenReaction | CC BY | 34857037 | 20,326,703 | 2021-12-02 |
What was the administration route of drug 'TRIAMCINOLONE ACETONIDE'? | Managing solar retinopathy with suprachoroidal triamcinolone acetonide injection in a young girl: a case report.
BACKGROUND
Solar retinopathy is a disease that causes photochemical toxicity in the retinal fovea tissues, leading to an acute decrease of vision.
METHODS
This case report is an interventional case of an a... | Ophthalmic | DrugAdministrationRoute | CC BY | 34857037 | 20,326,703 | 2021-12-02 |
What was the dosage of drug 'TRIAMCINOLONE ACETONIDE'? | Managing solar retinopathy with suprachoroidal triamcinolone acetonide injection in a young girl: a case report.
BACKGROUND
Solar retinopathy is a disease that causes photochemical toxicity in the retinal fovea tissues, leading to an acute decrease of vision.
METHODS
This case report is an interventional case of an a... | 0.1 MILLILITER (INJECTION WAS ADMINISTERED INSIDE THE SUPRACHOROIDAL SPACE WITH CUSTOM-MADE NEEDLE) | DrugDosageText | CC BY | 34857037 | 20,326,703 | 2021-12-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Introducing the importance and difficulties of a three-step approach to improve nonadherence to antihypertensive drugs: a case series.
Nonadherence to antihypertensive drugs is an important reason for not reaching blood pressure goals. A possible method to improve nonadherence involves three essential steps: identifica... | AMLODIPINE BESYLATE\HYDROCHLOROTHIAZIDE\VALSARTAN, BISOPROLOL, NIFEDIPINE, SPIRONOLACTONE | DrugsGivenReaction | CC BY | 34857710 | 20,961,409 | 2022-01-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Vertigo'. | Introducing the importance and difficulties of a three-step approach to improve nonadherence to antihypertensive drugs: a case series.
Nonadherence to antihypertensive drugs is an important reason for not reaching blood pressure goals. A possible method to improve nonadherence involves three essential steps: identifica... | AMLODIPINE BESYLATE\HYDROCHLOROTHIAZIDE\VALSARTAN, BISOPROLOL, NIFEDIPINE, SPIRONOLACTONE | DrugsGivenReaction | CC BY | 34857710 | 20,961,409 | 2022-01-01 |
What was the dosage of drug 'AMLODIPINE BESYLATE\HYDROCHLOROTHIAZIDE\VALSARTAN'? | Introducing the importance and difficulties of a three-step approach to improve nonadherence to antihypertensive drugs: a case series.
Nonadherence to antihypertensive drugs is an important reason for not reaching blood pressure goals. A possible method to improve nonadherence involves three essential steps: identifica... | 1 DOSAGE FORM, QD (COMBINATION TABLET) | DrugDosageText | CC BY | 34857710 | 20,961,409 | 2022-01-01 |
What was the dosage of drug 'BISOPROLOL'? | Introducing the importance and difficulties of a three-step approach to improve nonadherence to antihypertensive drugs: a case series.
Nonadherence to antihypertensive drugs is an important reason for not reaching blood pressure goals. A possible method to improve nonadherence involves three essential steps: identifica... | 10 MG, QD | DrugDosageText | CC BY | 34857710 | 20,961,409 | 2022-01-01 |
What was the dosage of drug 'SPIRONOLACTONE'? | Introducing the importance and difficulties of a three-step approach to improve nonadherence to antihypertensive drugs: a case series.
Nonadherence to antihypertensive drugs is an important reason for not reaching blood pressure goals. A possible method to improve nonadherence involves three essential steps: identifica... | 12.5 MG, QD | DrugDosageText | CC BY | 34857710 | 20,961,409 | 2022-01-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Arthralgia'. | Development of Rheumatoid Arthritis During Anti-Interleukin-5 Therapy in a Patient with Refractory Chronic Eosinophilic Pneumonia.
To report the case of a patient with refractory chronic eosinophilic pneumonia who developed rheumatoid arthritis during anti-interleukin (IL)-5 therapy.
The case of a 66-year-old male ex-s... | MEPOLIZUMAB, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 34858033 | 20,471,084 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Development of Rheumatoid Arthritis During Anti-Interleukin-5 Therapy in a Patient with Refractory Chronic Eosinophilic Pneumonia.
To report the case of a patient with refractory chronic eosinophilic pneumonia who developed rheumatoid arthritis during anti-interleukin (IL)-5 therapy.
The case of a 66-year-old male ex-s... | MEPOLIZUMAB, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 34858033 | 20,471,084 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Joint stiffness'. | Development of Rheumatoid Arthritis During Anti-Interleukin-5 Therapy in a Patient with Refractory Chronic Eosinophilic Pneumonia.
To report the case of a patient with refractory chronic eosinophilic pneumonia who developed rheumatoid arthritis during anti-interleukin (IL)-5 therapy.
The case of a 66-year-old male ex-s... | MEPOLIZUMAB, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 34858033 | 20,471,084 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Rheumatoid arthritis'. | Development of Rheumatoid Arthritis During Anti-Interleukin-5 Therapy in a Patient with Refractory Chronic Eosinophilic Pneumonia.
To report the case of a patient with refractory chronic eosinophilic pneumonia who developed rheumatoid arthritis during anti-interleukin (IL)-5 therapy.
The case of a 66-year-old male ex-s... | MEPOLIZUMAB, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 34858033 | 20,471,084 | 2021 |
What was the administration route of drug 'MEPOLIZUMAB'? | Development of Rheumatoid Arthritis During Anti-Interleukin-5 Therapy in a Patient with Refractory Chronic Eosinophilic Pneumonia.
To report the case of a patient with refractory chronic eosinophilic pneumonia who developed rheumatoid arthritis during anti-interleukin (IL)-5 therapy.
The case of a 66-year-old male ex-s... | Subcutaneous | DrugAdministrationRoute | CC BY-NC | 34858033 | 20,471,084 | 2021 |
What was the administration route of drug 'PREDNISOLONE'? | Development of Rheumatoid Arthritis During Anti-Interleukin-5 Therapy in a Patient with Refractory Chronic Eosinophilic Pneumonia.
To report the case of a patient with refractory chronic eosinophilic pneumonia who developed rheumatoid arthritis during anti-interleukin (IL)-5 therapy.
The case of a 66-year-old male ex-s... | Oral | DrugAdministrationRoute | CC BY-NC | 34858033 | 20,471,084 | 2021 |
What was the outcome of reaction 'Arthralgia'? | Development of Rheumatoid Arthritis During Anti-Interleukin-5 Therapy in a Patient with Refractory Chronic Eosinophilic Pneumonia.
To report the case of a patient with refractory chronic eosinophilic pneumonia who developed rheumatoid arthritis during anti-interleukin (IL)-5 therapy.
The case of a 66-year-old male ex-s... | Recovered | ReactionOutcome | CC BY-NC | 34858033 | 20,471,084 | 2021 |
What was the outcome of reaction 'Drug ineffective'? | Development of Rheumatoid Arthritis During Anti-Interleukin-5 Therapy in a Patient with Refractory Chronic Eosinophilic Pneumonia.
To report the case of a patient with refractory chronic eosinophilic pneumonia who developed rheumatoid arthritis during anti-interleukin (IL)-5 therapy.
The case of a 66-year-old male ex-s... | Recovered | ReactionOutcome | CC BY-NC | 34858033 | 20,471,084 | 2021 |
What was the outcome of reaction 'Joint stiffness'? | Development of Rheumatoid Arthritis During Anti-Interleukin-5 Therapy in a Patient with Refractory Chronic Eosinophilic Pneumonia.
To report the case of a patient with refractory chronic eosinophilic pneumonia who developed rheumatoid arthritis during anti-interleukin (IL)-5 therapy.
The case of a 66-year-old male ex-s... | Recovered | ReactionOutcome | CC BY-NC | 34858033 | 20,471,084 | 2021 |
What was the outcome of reaction 'Rheumatoid arthritis'? | Development of Rheumatoid Arthritis During Anti-Interleukin-5 Therapy in a Patient with Refractory Chronic Eosinophilic Pneumonia.
To report the case of a patient with refractory chronic eosinophilic pneumonia who developed rheumatoid arthritis during anti-interleukin (IL)-5 therapy.
The case of a 66-year-old male ex-s... | Recovered | ReactionOutcome | CC BY-NC | 34858033 | 20,471,084 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Arthralgia'. | Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bone metastases (BMs) are a negative prognostic factor in patients with non-small cell lung cancer (NSCLC). Although immune-checkpoint inhibitors (ICIs... | ATEZOLIZUMAB, DENOSUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34858389 | 19,907,952 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Asthenia'. | Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bone metastases (BMs) are a negative prognostic factor in patients with non-small cell lung cancer (NSCLC). Although immune-checkpoint inhibitors (ICIs... | ATEZOLIZUMAB, DENOSUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34858389 | 19,907,952 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Blood creatinine increased'. | Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bone metastases (BMs) are a negative prognostic factor in patients with non-small cell lung cancer (NSCLC). Although immune-checkpoint inhibitors (ICIs... | ATEZOLIZUMAB, DENOSUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34858389 | 19,907,952 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Death'. | Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bone metastases (BMs) are a negative prognostic factor in patients with non-small cell lung cancer (NSCLC). Although immune-checkpoint inhibitors (ICIs... | ATEZOLIZUMAB, DENOSUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34858389 | 19,907,952 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Dermatitis'. | Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bone metastases (BMs) are a negative prognostic factor in patients with non-small cell lung cancer (NSCLC). Although immune-checkpoint inhibitors (ICIs... | ATEZOLIZUMAB, DENOSUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34858389 | 19,907,952 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Diarrhoea'. | Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bone metastases (BMs) are a negative prognostic factor in patients with non-small cell lung cancer (NSCLC). Although immune-checkpoint inhibitors (ICIs... | ATEZOLIZUMAB, DENOSUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34858389 | 19,907,952 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Dyspnoea'. | Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bone metastases (BMs) are a negative prognostic factor in patients with non-small cell lung cancer (NSCLC). Although immune-checkpoint inhibitors (ICIs... | ATEZOLIZUMAB, DENOSUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34858389 | 19,907,952 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hyperamylasaemia'. | Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bone metastases (BMs) are a negative prognostic factor in patients with non-small cell lung cancer (NSCLC). Although immune-checkpoint inhibitors (ICIs... | ATEZOLIZUMAB, DENOSUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34858389 | 19,907,952 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypertransaminasaemia'. | Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bone metastases (BMs) are a negative prognostic factor in patients with non-small cell lung cancer (NSCLC). Although immune-checkpoint inhibitors (ICIs... | ATEZOLIZUMAB, DENOSUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34858389 | 19,907,952 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypocalcaemia'. | Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bone metastases (BMs) are a negative prognostic factor in patients with non-small cell lung cancer (NSCLC). Although immune-checkpoint inhibitors (ICIs... | ATEZOLIZUMAB, DENOSUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34858389 | 19,907,952 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypophosphataemia'. | Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bone metastases (BMs) are a negative prognostic factor in patients with non-small cell lung cancer (NSCLC). Although immune-checkpoint inhibitors (ICIs... | ATEZOLIZUMAB, DENOSUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34858389 | 19,907,952 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypothyroidism'. | Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bone metastases (BMs) are a negative prognostic factor in patients with non-small cell lung cancer (NSCLC). Although immune-checkpoint inhibitors (ICIs... | ATEZOLIZUMAB, DENOSUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34858389 | 19,907,952 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Infection'. | Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bone metastases (BMs) are a negative prognostic factor in patients with non-small cell lung cancer (NSCLC). Although immune-checkpoint inhibitors (ICIs... | ATEZOLIZUMAB, DENOSUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34858389 | 19,907,952 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Lipase increased'. | Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bone metastases (BMs) are a negative prognostic factor in patients with non-small cell lung cancer (NSCLC). Although immune-checkpoint inhibitors (ICIs... | ATEZOLIZUMAB, DENOSUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34858389 | 19,907,952 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nephropathy toxic'. | Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bone metastases (BMs) are a negative prognostic factor in patients with non-small cell lung cancer (NSCLC). Although immune-checkpoint inhibitors (ICIs... | ATEZOLIZUMAB, DENOSUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34858389 | 19,907,952 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neuropathy peripheral'. | Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bone metastases (BMs) are a negative prognostic factor in patients with non-small cell lung cancer (NSCLC). Although immune-checkpoint inhibitors (ICIs... | ATEZOLIZUMAB, DENOSUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34858389 | 19,907,952 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neutropenia'. | Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bone metastases (BMs) are a negative prognostic factor in patients with non-small cell lung cancer (NSCLC). Although immune-checkpoint inhibitors (ICIs... | ATEZOLIZUMAB, DENOSUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34858389 | 19,907,952 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neutrophil/lymphocyte ratio decreased'. | Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bone metastases (BMs) are a negative prognostic factor in patients with non-small cell lung cancer (NSCLC). Although immune-checkpoint inhibitors (ICIs... | ATEZOLIZUMAB, DENOSUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34858389 | 19,907,952 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Osteonecrosis of jaw'. | Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bone metastases (BMs) are a negative prognostic factor in patients with non-small cell lung cancer (NSCLC). Although immune-checkpoint inhibitors (ICIs... | ATEZOLIZUMAB, DENOSUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34858389 | 19,907,952 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pneumonitis'. | Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bone metastases (BMs) are a negative prognostic factor in patients with non-small cell lung cancer (NSCLC). Although immune-checkpoint inhibitors (ICIs... | ATEZOLIZUMAB, DENOSUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34858389 | 19,907,952 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Rash'. | Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bone metastases (BMs) are a negative prognostic factor in patients with non-small cell lung cancer (NSCLC). Although immune-checkpoint inhibitors (ICIs... | ATEZOLIZUMAB, DENOSUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34858389 | 19,907,952 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Sepsis'. | Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bone metastases (BMs) are a negative prognostic factor in patients with non-small cell lung cancer (NSCLC). Although immune-checkpoint inhibitors (ICIs... | ATEZOLIZUMAB, DENOSUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34858389 | 19,907,952 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Skin toxicity'. | Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bone metastases (BMs) are a negative prognostic factor in patients with non-small cell lung cancer (NSCLC). Although immune-checkpoint inhibitors (ICIs... | ATEZOLIZUMAB, DENOSUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34858389 | 19,907,952 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapy partial responder'. | Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bone metastases (BMs) are a negative prognostic factor in patients with non-small cell lung cancer (NSCLC). Although immune-checkpoint inhibitors (ICIs... | ATEZOLIZUMAB, DENOSUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34858389 | 19,907,952 | 2021 |
What was the outcome of reaction 'Death'? | Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bone metastases (BMs) are a negative prognostic factor in patients with non-small cell lung cancer (NSCLC). Although immune-checkpoint inhibitors (ICIs... | Fatal | ReactionOutcome | CC BY | 34858389 | 19,907,952 | 2021 |
What was the outcome of reaction 'Dermatitis'? | Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bone metastases (BMs) are a negative prognostic factor in patients with non-small cell lung cancer (NSCLC). Although immune-checkpoint inhibitors (ICIs... | Recovered | ReactionOutcome | CC BY | 34858389 | 19,907,952 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapeutic product effect incomplete'. | Case report of primary CD20 negative diffuse large B-cell lymphoma.
Few groups of aggressive non-Hodgkin's lymphomas (NHL) that are refractory to standard chemotherapy are rarely reported. Primary CD20 negative diffuse large B cell lymphoma (DLBCL) without human immunodeficiency virus infection is an uncommon presentat... | CISPLATIN, CYCLOPHOSPHAMIDE, DEXAMETHASONE, DOXORUBICIN, ETOPOSIDE, GEMCITABINE, PREDNISOLONE, VINCRISTINE | DrugsGivenReaction | CC BY-NC | 34858628 | 20,343,526 | 2021-11 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Treatment failure'. | Case report of primary CD20 negative diffuse large B-cell lymphoma.
Few groups of aggressive non-Hodgkin's lymphomas (NHL) that are refractory to standard chemotherapy are rarely reported. Primary CD20 negative diffuse large B cell lymphoma (DLBCL) without human immunodeficiency virus infection is an uncommon presentat... | CISPLATIN, CYCLOPHOSPHAMIDE, DEXAMETHASONE, DOXORUBICIN, ETOPOSIDE, GEMCITABINE, PREDNISOLONE, VINCRISTINE | DrugsGivenReaction | CC BY-NC | 34858628 | 20,343,526 | 2021-11 |
What was the dosage of drug 'CISPLATIN'? | Case report of primary CD20 negative diffuse large B-cell lymphoma.
Few groups of aggressive non-Hodgkin's lymphomas (NHL) that are refractory to standard chemotherapy are rarely reported. Primary CD20 negative diffuse large B cell lymphoma (DLBCL) without human immunodeficiency virus infection is an uncommon presentat... | I.E. GCD | DrugDosageText | CC BY-NC | 34858628 | 20,343,526 | 2021-11 |
What was the dosage of drug 'CYCLOPHOSPHAMIDE'? | Case report of primary CD20 negative diffuse large B-cell lymphoma.
Few groups of aggressive non-Hodgkin's lymphomas (NHL) that are refractory to standard chemotherapy are rarely reported. Primary CD20 negative diffuse large B cell lymphoma (DLBCL) without human immunodeficiency virus infection is an uncommon presentat... | REGIMEN I.E. EPOCH | DrugDosageText | CC BY-NC | 34858628 | 20,343,526 | 2021-11 |
What was the dosage of drug 'DEXAMETHASONE'? | Case report of primary CD20 negative diffuse large B-cell lymphoma.
Few groups of aggressive non-Hodgkin's lymphomas (NHL) that are refractory to standard chemotherapy are rarely reported. Primary CD20 negative diffuse large B cell lymphoma (DLBCL) without human immunodeficiency virus infection is an uncommon presentat... | I.E. GCD | DrugDosageText | CC BY-NC | 34858628 | 20,343,526 | 2021-11 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.